Published: 2025-11-10

In-Depth Reviews

Original Research

A Comparative Analysis of Intralesional Injection Triamcinolone Acetonide, Injection Bleomycin, and Radiofrequency Ablation in the treatment of keloids

Aarti Singh, Ghanshyam Kumar Verma, Renu Rattan, Ranjani Sharma, Aditya Saini, Diksha Bhandari

Page 2728-2737

Medical Education in Dermatology

NIH Funding and Research Output of Dermatology Applicants Before and After STEP 1 Pass/Fail Transition

Ameena Ali, Asim Ahmed , Arjun N. Bhatt , Ali Abolhassani , Jackson McClain, Hana I. Nazir , Loretta S. Davis

Page 2738-2741

Research Letters

Prevalence of Primary Epithelioid Sarcoma in the United States: A Cross-sectional Study Using the SEER Database

Shangyi Fu, Ramlah Khan , Darien Hinson, Melissa Marchan-Martinez, Diana Bonilla, Ibeth Caceres, Danny Huynh

Page 2742-2745

Brief Articles

Kratom-Induced Photodistributed Hyperpigmentation: A Case Report

Sonia P. Goyal, BS, Neal Varughese, MD, MBA

Page 2752-2756

Biology Beyond the Margins: Impact of 40-Gene Expression Profiling on Risk Stratification in Cutaneous Squamous Cell Carcinoma

Heather Gates, PA-C, DFAAPA, Cynthia Trickett, PA-C, Tiffani Botts Massey, PA-C, Francine Phillips, PA-C, Patrice Simon, PA-C, Angela Rosenberg, DO, Darrell Rigel, MD

Page 2757-2761

Risk Stratification for Melanoma Using the 31-Gene Expression Profile Test: A Case Report

AnnMarie Skelton, Carmen Boyd, Valerie Cooper, Olga Forman, Lauren Miller

Page 2762-2764

Use of Tralokinumab in the Management of Bullous Pemphigoid

Emily Tocco, Margaret Mercante, Diego Ruiz Dasilva

Page 2765-2768

PDF KOL SUMMARY

Reassessing Potential Triggering Factors and Trends in Periorificial Dermatitis: A 12-Year Retrospective Cohort Study

Haley Neff, Yuying Zhang, Ryan Chen, Carolyn Foley, Kelton Do, Christopher Mahir, Julie Flahive, Dr. Nikki A Levin

Page 2769-2775

Clue to Diagnosis: Flagellate Erythema in Anti-MDA5 Antibody-Positive Dermatomyositis in a Patient with Skin of Color

Ekaterina Korytnikova, Anastasiia Sumenkova, Victor Cazac, Patrick Webster, Charles L. Halasz

Page 2781-2785

Atypical Presentation of Merkel Cell Carcinoma: A Case Report

Ibraheim Ayub, DO, Brittany Snyder, DO, PharmD, Michael DeWall, DO, Sakeena Fatima, MD

Page 2790-2793

Short Communications

SKINmages: Clinical Images in Dermatology

Aggressive Squamous Cell Carcinoma in a Transplant Recipient

Grace Boyd, Jessica Terrell, Dr. Michael O. Nguyen

Page 2799-2802

When the Skin Remembers: A Delayed Reaction to Corticosteroid Injection

Ekaterina Korytnikova, Vanessa Barber, Charles L. Halasz

Page 2803-2805

Compelling Comments

Overcoming the Pitfalls of External Bolsters on Nasal Alar Skin Grafts Using Intranasal Dental Rolls

Vlad Codrea, Adelle Pacyna, Sarah Campbell, Julian Stashower

Page 2808-2809

Poster Presentations from FC25 Dermatology Conference®: Atopic Dermatitis

Patients with Atopic Dermatitis Reported Rapid and Optimal Real-World Effectiveness with Upadacitinib: SCALE-UP Study Results by Prior Treatment

Jonathan I Silverberg, Brian Calimlim, Zelma C Chiesa Fuxench, Diego Ruiz Dasilva, Arielle G Bensimon, Jiaxuan Liu, Ayman Grada, Chao Li, Bang Truong, Christopher G Bunick

Page s590

Ruxolitinib Cream is Associated With Reduced Treatment Burden in Atopic Dermatitis: A US Payer Claim Analysis

Karen Miller; Jinan Liu, Bonnie H. Bui, Nnaemeka U. Odo, Tim Bancroft, Daniel Sturm

Page s591

Real-World Effectiveness of Upadacitinib in Moderate-to-Severe Atopic Dermatitis: Results from Longitudinal Analyses in 6- and 12-month Cohorts From the PPD CorEvitas Atopic Dermatitis Registry

Jonathan I Silverberg, Melinda Gooderham, Christopher G. Bunick, Brian Calimlim, Ayman Grada, Yolanda Munoz Maldonado, Alvin H Li, Nicole Fergestrom, Eric Simpson

Page s592

Individual Clinical Response Trajectories to Lebrikizumab in Atopic Dermatitis: A Cluster Analysis

Andrew Blauvelt, Bruce Strober, Gaia Gallo, Yuxin Ding, Yun-Fei Chen, MartinDossenbach, Lidia Rodriguez Calleja, Linda Stein Gold, Jonathan Silverberg

Page s595

Impact of Dupilumab on the Ability to Enjoy Life in Patients With Moderate-to-Severe Atopic Dermatitis

Alexa B. Kimball, Min Yang, Bruno Martins, Ashley Holub, Jingdong Chao, Gaëlle Bégo-Le-Bagousse, Kerry Noonan, Zhixiao Wang

Page s596

Impact of Dupilumab on Education and Career in Patients With Moderate-to-Severe Atopic Dermatitis

Alexa B. Kimball, Min Yang, Bruno Martins, Ashley Holub, Jingdong Chao, Gaëlle Bégo-Le-Bagousse, Kerry Noonan, Zhixiao Wang

Page s597

Stable Clear-Almost Clear Response is Sustained up to 3 Years in Patients with Moderate-To-Severe Atopic Dermatitis Treated With Lebrikizumab

Jonathan I. Silverberg, Linda Stein Gold, Peter Lio, James Del Rosso, Andreas Wollenberg, Jose Manuel Carrascosa, Gaia Gallo, Eric Wolf, Yuxin Ding, Chao Yang, Helena Agell, Christian Vestergaard

Page s599

Durability of Response After Pausing Abrocitinib Treatment in Patients With Moderate-to-Severe Atopic Dermatitis

Stephan Weidinger, Yoko Kataoka, Brian S. Kim, Irina Lazariciu, Gerardo Encinas, Melissa Watkins, Herwig Koppensteiner

Page s600

Lebrikizumab Dosed Every 8 Weeks as Maintenance Provides Long-Lasting Response in Patients with Moderate-to-Severe Atopic Dermatitis

Kathy Oneacre, Jonathan I Silverberg, Vivian Laquer, Peter Lio, Kim Papp, Alan Irvine, Andrew Blauvelt, Hany Elmaraghy, Louise DeLuca-Carter, Heidi Crane, Gaia Gallo, Evangeline Pierce, Yuxin Ding, Amy S. Paller

Page s601

Interim Safety Results of Amlitelimab (anti-OX40 ligand antibody) in Participants With Moderate-to-Severe Atopic Dermatitis From the RIVER-AD Phase 2/3 Ongoing Open-Label Study

Kircik Leon, Ken Igawa, Pedro Herranz Pinto, Hang Li, Yanzhen Wu, Zuzana Hajasova, Charlotte Bernigaud, Sonya Davey, Samuel Adelman

Page s602

Amlitelimab Reduces Th2-, Th1-, and Th17/22-Related Cytokines and Chemokines in Adults With Moderate-to-Severe Atopic Dermatitis: Results From an Exploratory Analysis of the Phase 2b STREAM-AD Study

Bob Geng, Stephan Weidinger, Saeko Nakajima, Donald Leung, Charles Lynde, Karl Yen, Jason Deng, Shaima Belhechmi, Natalie Rynkiewicz

Page s603

Impact of Amlitelimab (An Anti-OX40 Ligand Antibody) on Maintenance of Itch Response in Atopic Dermatitis: Results From the 52-Week STREAM-AD Phase 2b Study

Brian S Kim, Yoko Kataoka, Andrew Blauvelt, Stephan Weidinger, Gil Yosipovitch, Delphine Staumont-Sallé, Anne-Catherine Solente, Kassim Rahawi, Sonya Davey

Page s604

Durable maintenance of EASI-90 with amlitelimab in adults with moderate-to-severe atopic dermatitis: 52-week results from the STREAM-AD phase 2b trial

Andrew Blauvelt, Bruce Strober, April Armstrong, Ken Igawa, Nina Magnolo, Pei Li, Charlotte Bernigaud, Sonya Davey, Kassim Rahawi

Page s606

Long-Term Durability and Stability of Amlitelimab Efficacy in Adults With Moderate-to-Severe Atopic Dermatitis: 52-Week Post Hoc Analysis of the STREAM-AD Phase 2b Trial

Linda Stein Gold, Bruce Strober, Julien Seneschal, Ken Igawa, Jianjun Qiao, Nicole Armstrong, Kassim Rahawi, Chia-Hui Chung

Page s607

The Impact of Moderate-to-Severe Atopic Dermatitis on Sleep in Adolescent Patients from the Adelphi Real World Disease Specific Programme (DSP)TM

Dr Amy Paller, Dr Vimal H. Prajapati, Dr Mercedes E. Gonzalez, Dr Evangeline Pierce, Dr Zach Dawson, Dr Eric Wolf, Ms. Niamh Harvey, Mr. Oliver Howell, Mr. David Bell, Dr Lawrence F. Eichenfield

Page s608

Lebrikizumab Patients Treated in the Real World: First North American data from the PPDTM CorEvitasTM AD Registry

Eric Simpson, Vimal H. Prajapati, William A. McCann, Dr Zach Dawson, Evangeline Pierce, Alvin H. Li, C. Jean Choi, Jonathan I. Silverberg

Page s609

Understanding Topical Treatment Experiences in Patients with Moderate-to-Severe Atopic Dermatitis: Results from a US Cross-sectional Survey

Peter Lio, Autumn Burnette, Alexa Hetzel, Zach Dawson, Evangeline Pierce, Rosie Fielding, James Haughton, Linda Stein Gold

Page s610

Efficacy of Upadacitinib vs Dupilumab Treatment for Moderate‑to‑Severe Atopic Dermatitis: Analysis of Time Spent in Response State From the Level Up Study

Bruno Duarte, Raj Chovatiya, Diamant Thaçi, Vivian Shi, Bin Yang, Jordan Talia, Aisaku Yamamoto, David Prefontaine, Varinder S. Punia, Alena Pechonkina, Michael Lane, Brian M. Calimlim, Jonathan I. Silverberg

Page s611

Patients With Cardiovascular Risk Factors and Atopic Dermatitis: Long-Term Safety of Upadacitinib for Major Adverse Cardiovascular Events, Venous Thromboembolism, or Malignancy (Excluding Nonmelanoma Skin Cancer)

Christopher G. Bunick, Linda F. Stein Gold, Ruth Ann Vleugels, Raj Chovatiya, David G. Cotter, Matthew Zirwas, Paula Carolina Luna, Chia-Yu Chu, Ayman Grada, Deanne M. Dilley, Meerat Oza, Alena Pechonkina, Lani Wegrzyn, Gweneth F. Levy, Jonathan I. Silverberg

Page s612

Patients With Atopic Dermatitis Using Oral Contraceptive Pills or Hormone Replacement Therapy: Long-Term Safety of Upadacitinib for Major Adverse Cardiovascular Events, Venous Thromboembolism, or Malignancy (Excluding Nonmelanoma Skin Cancer)

Linda F. Stein Gold, Mona Shahriari, Emma Guttman-Yassky, Raj Chovatiya, David G. Cotter, Matthew Zirwas, Ruth Ann Vleugels, Paula Carolina Luna, Chia-Yu Chu, Christopher G. Bunick, Ayman Grada, Deanne M. Dilley, Alena Pechonkina, Lani Wegrzyn, Gweneth F. Levy, Jonathan I. Silverberg

Page s613

Patients With a Smoking History and Atopic Dermatitis: Long-Term Safety of Upadacitinib for Major Adverse Cardiovascular Events, Venous Thromboembolism, or Malignancy (Excluding Nonmelanoma Skin Cancer)

Naiem T. Issa, Linda F. Stein Gold, Emma Guttman-Yassky, Michael C. Cameron, David G. Cotter, Matthew Zirwas, Raj Chovatiya, Ruth Ann Vleugels, Paula Carolina Luna, Chia-Yu Chu, Christopher G. Bunick, Ayman Grada, Deanne M. Dilley, Varinder S. Punia, Lani Wegrzyn, Gweneth F. Levy, Jonathan I. Silverberg

Page s614

Skin Clearance and Itch Relief in Black or African American Patients with Moderate-to-Severe Atopic Dermatitis Treated with Upadacitinib: 140-Week Outcomes from Integrated Phase 3 Measure Up 1 and 2 Studies

Andrew Alexis, Adam Friedman, Nada Elbuluk, Karan Lal, Mona Shahriari, Chesahna Kindred, Chibuzo Obi, Michael Lane, Brian M. Calimlim, Ayman Grada, Seemal Desai

Page s615

Integrated Safety Analysis of Abrocitinib in 3850 Patients With Moderate-To-Severe Atopic Dermatitis: Data From More Than 9600 Patient-Years With Up to 6.5 Years of Exposure

Eric L. Simpson, Alan D. Irvine, Jan Gutermuth, H. Chih-Ho Hong, Raj Chovatiya, Emma Guttman-Yassky, Haiyun Fan, Gary Chan, Cristina Lumpan, Justine Alderfer, Herwig Koppensteiner

Page s616

Patients With Moderate-to-Severe Atopic Dermatitis Maintained Depth of Response Up to 2 Years With Continuous Abrocitinib Treatment

Emma Guttman-Yassky, Peter Lio, Andreas Wollenberg, Sonja Ständer, Fang Wang, Gary Chan, Pinaki Biswas, Melissa Watkins

Page s617

Flexible Dosing of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Initial Results From the Real-World–Simulating Expanded Access Protocol Study, JADE REAL

Raj Chovatiya, Matthew Zirwas, Eric L. Simpson, Melinda J. Gooderham, Marjolein de Bruin-Weller, Stephan Weidinger, Pinaki Biswas, Gary Chan, Herwig Koppensteiner

Page s618

C-206 Real-World Prospective Data Assessing the Long-Term Safety of Abrocitinib Treatment in Adults with Moderate to Severe Atopic Dermatitis (AD): Over Two Years of Experience from the CorEvitas AD Registry [1225]

Sampada Gandhi, Bernice Gershenson, Heather Chubb, Bryan Cherry, Nathan Rubin, Christine J. Barr, Melissa Moore-Clingenpeel, Dimitrios A. Pappas, Haiyun Fan, Cristina Lumpan, Jen Weissert, Pinaki Biswas, Gary Chan

Page s619

Impact of Moderate-to-Severe Atopic Dermatitis on Daily Functioning among Adolescent Patients: A Real-World Study in the United States

Amy S. Paller, Vimal H. Prajapati, Mercedes E. Gonzalez, Zach Dawson, Evangeline Pierce, Eric Wolf, Niamh Harvey, Oliver Howell, David Bell, Lawrence F. Eichenfield

Page s620

The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective, multi-center trial

Jonathan I. Silverberg, Lawrence F. Eichenfield, April Armstrong, Erin Boh, John Koo, Jerry Bagel, Ben Lockshin, Aaron Farberg, Matthew S. Goldberg, Ann P. Quick, Mark G. Lebwohl

Page s621

Treatment Satisfaction with Topical Therapies in Adolescent and Adult Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Study in the United States

Peter Lio, Autumn Burnette, Alexa Hetzel, Zach Dawson, Evangeline J Pierce, Rosie Fielding, James Haughton, Linda Stein Gold

Page s622

An Interim Analysis of a Prospective Observational Study of Upadacitinib in Patients with Atopic Dermatitis with Prurigo Nodules

Hiroyuki Murota, Teppei Hagino, Hidetoshi Takahashi, Shintaro Takeoka, Sei-ichiro Motegi, Motoi Takenaka, Takeshi Ishido, Hiroyuki Hozawa, Yayoi Tada

Page s623

Impact of Simultaneous Itch Relief and Substantial Skin Clearance With Lebrikizumab in Patients With Atopic Dermatitis: Post-hoc Analysis From ADvocate1/2

Raj Chovatiya, Khai Jing Ng, H. Chih-Ho Hong, Yousef Binamer, Evangeline Pierce, Meihua Qiao, Eric Wolf, Melinda Gooderham

Page s624

Lebrikizumab Treatment Improves Lichenification and Other Clinical Signs of Atopic Dermatitis in Adults and Adolescents with Moderate-to-Severe AD and Skin of Color

Chesahna Kindred, Raj Chovatiya, Jill Waibel, H. Chih-ho Hong, Zach Dawson, Jinglin Zhong, Lucia Seminario-Vidal, Andrew Alexis, Immunology Publications

Page s625

Tapinarof Cream 1% Once Daily: Consistent Efficacy Across Age Groups for Children Down to 2 Years of Age with Atopic Dermatitis in Two Pivotal Phase 3 Trials

Luz Fonacier, Mark Boguniewicz, Jason Ohayon, Philip M. Brown, David S. Rubenstein, Anna M. Tallman, Jonathan I. Silverberg

Page s626

Treatment Patterns and Efficacy in Biologic-Exposed and Biologic-Naive Patients With Moderate-to-Severe Atopic Dermatitis: JADE REAL Post Hoc Analysis

Melinda J Gooderham, Raj Chovatiya, Stephan Weidinger, Zhao Zuotao, Yukari Okubo, Irina Lazariciu, Herwig Koppensteiner, Simon Chen, Carmen Tsang

Page s627

Tapinarof Cream 1% Once Daily: Maintenance of Low Disease Activity Including Pruritus Through End of the Treatment-freeInterval in a Long-term Extension Trial in Patients Down to 2 Years of Age with Atopic Dermatitis

Jonathan I. Silverberg, Robert Bissonnette, Linda Stein Gold, Philip M. Brown, Mark Boguniewicz, David Rosmarin, Autumn F. Burnette, Wendy Cantrell, Matthew J. Bruno, Anna M. Tallman

Page s628

The Potent and Selective Oral STAT6 Degrader, KT-621, Affects Gene Transcripts in Human Keratinocytes as Effectively as Dupilumab, and Blocks Th2 Inflammation in Atopic Dermatitis and Asthma Mouse Models

Amy Wang, Bin Yang, Karen Yuan, Alamgir Hossain, Rahul Karnik, James Shaw, Huijun Dong, Bruce Follows, Chris Browne, Ralf Schmidt, Rupa Sawant, Bradley Enerson, Chad Nivens, Nello Mainolfi

Page s629

Estimated Conjunctivitis-Related Healthcare Cost Savings With Increased Tralokinumab Use Versus Other Biologics Among Patients With Moderate-Severe Atopic Dermatitis in the United States

Sanjeev Balu, Jessica Maitland, Marjolaine Gauthier-Loiselle, Remi Bellefleur, Holly Arscott, Annie Guerin, Hannah Lo, Aseel Bin Sawad

Page s630

Psoriasis

A Phase 4 Multicenter, Randomized, Open-Label, Efficacy Assessor-Blinded Study of Risankizumab Compared With Deucravacitinib for the Treatment of Adult Patients With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy: 16-Week Results From IMMpactful

Nina Magnolo, Jennifer Soung, John Frew, Antonio Costanzo, Mar Llamas-Velasco, Michael Bukhalo, Raja Sivamani, Angela Moore, Tianshuang Wu, Jiaheng Xie, Manish Patel, Doug Ashley, Blair Kaplan, Vassilis Stakias, Ramon Espaillat, Richard B. Warren

Page s631

Real-World Clinician- and Patient-Reported Outcomes and Treatment Persistence Following Bimekizumab Initiation in Patients with Psoriasis: 6-Month Results from the PPD CorEvitas Psoriasis Registry

Bruce Strober, Michael Singleton, Alvin H. Li, Rhiannon Dodge, Wanyi Chen, Kayla Callahan, Megan Phillips, Prajakta Masurkar, Heather Herr, Braulio Gomez, Robert Low, Jeffrey Stark

Page s632

EVERLAST-A: A Phase 2a Study Design of ORKA-001, a Novel Half-Life Extended IL-23p19 Monoclonal Antibody for Plaque Psoriasis

Andrew Blauvelt MD, MBA, Bruce Strober, MD, PhD, Joseph Merola, MD, MMSc, James Krueger MD, PhD, Joel Gelfand, MD, MSCE, FAAD, Johann Gudjonsson, MD, PhD, Eugenia Levi, PharmD, Dr. Joana Goncalves, Mark Lebwohl, MD

Page s633

Phase 1 Clinical Data of ORKA-001, a Novel Half-Life Extended IL-23p19 Monoclonal Antibody with Potential for Once-Yearly Dosing in Plaque Psoriasis

James Krueger MD, PhD, Chris Wynne, MBChB, FRACR, DPharm Med , Mark Lebwohl, MD, Bruce Strober, MD, PhD, Joseph Merola, MD, MMSc, Joel Gelfand, MD, MSCE, FAAD, Johann Gudjonsson, MD, PhD, Becky Blanchard PhD, Christopher Finch, Eugenia Levi, PharmD, Dr. Joana Goncalves, Andrew Blauvelt MD, MBA

Page s634

Efficacy of Risankizumab on Symptoms in Patients With Scalp Psoriasis in a Post-Hoc Analysis of the UnlIMMited Phase 4 Randomized Clinical Trial at Week 16

Eingun James Song, Phoebe Rich, Navid Ezra, Harrison Nguyen, Priya S. Mathur, Brenton Bialik, Chenyang Duan, Richard Ta, Toni Anschutz, Lindsay Ackerman

Page s636

EFFISAYIL OBSERVE: A real-world descriptive study of patients with generalized pustular psoriasis (GPP) in the USA

Mark G. Lebwohl, Raj Chovatiya, Laura K. Ferris, Kori Stetter, Becca S. Feldman, Brent E. Mancha, Ikenna Unigwe, Nichiren Pillai, Bhargav Lakshminarasimhan, Jason Guercio, Alice B. Gottlieb

Page s637

Perceptions of Living with and Managing Both Psoriatic Disease and Overweight/Obesity: A Qualitative Interview Study

Urvi Desai, Beth Mitchell, Andrea Cohee, Yao Wang, Ashley Holub, Matthew Mattera, Ellen Sears, Catherine Bakewell, Tina Bhutani Jacques, Noam Kirson, Heather Stuckey-Peyrot

Page s638

High Prevalence of Obesity and Related Complications with Limited Utilization of Obesity Medication in Patients with Psoriasis or Psoriatic Arthritis: Real-World Clinical Insights from the US

Mark Lebwohl, Orrin Troum, Jeffrey R. Curtis, Andrew Blauvelt, Ronald Prussick, Sakil Syeed, Beth Mitchell, Najwa Somani, Natalia Bello, Marie Louise Edwards, Joseph F. Merola

Page s639

Health Care Resource Utilization Over Time in Patients with Psoriatic Disease, Stratified by BMI

Stephen Shields, Ann Von Holle, Rachael Zuckerman, Russel Burge, Beth Mitchell, Susan Ball, Joseph F. Merola, Elizabeth Ciemins

Page s640

Comparative Durability of Biologics for Patients With Moderate-to-Severe Psoriasis Adjusted for Drug Switching Over Time: 24-Month Outcomes From the International Observational Psoriasis Study of Health Outcomes (PSoHO)

Andreas Pinter, Alan Brnabic, Emanuele Trovato, Lluis Puig, Jose-Manuel Carrascosa, Thierry Boyé, Matteo Megna, Silvia Sabatino, Inmaculada De La Torre, Julia-Tatjana Maul

Page s641

Impact and Insights of Psoriasis on Quality of Life and Shared Decision-making among US Adolescents and Adults

Linda Stein Gold,  Jennifer Soung, Nina Trenkler, Ashley Duenas,  Laurie Conklin,  Jensen Lewis,  Timothy Fitzgerald, Gale Harding,  Ya-Wen Yang, Guo Li,  Mona Shahriari

Page s643

Unmet Needs and Disease Burden: Perspectives from Adults with Psoriasis and Clinicians Treating Psoriasis in the US

Linda Stein Gold, Jennifer Soung, Nina Trenkler, Melina Taylor, Laurie Conklin, Jensen Lewis, Timothy Fitzgerald, Wesley Peters, Ya-Wen Yang, Guo Li, Mona Shahriari

Page s644

Bimekizumab long-term efficacy in patients with plaque psoriasis from BE BRIGHT: Improvements in mean absolute clinical outcome scores over 4 years

Sascha Gerdes, Antonio Costanzo, Pablo Fernandez-Peñas, Khusru Asadullah, Andrew Blauvelt, Álvaro González-Cantero, Sarah Kavanagh, José Manuel López Pinto, Bengt Hoepken, George Han

Page s645

Bimekizumab rates of oral candidiasis in patients with moderate to severe plaque psoriasis: Results from up to 4 years of five phase 3/3b studies

Richard B. Warren, Diamant Thaçi, April Armstrong, Melinda Gooderham, Kenneth B. Gordon, Balint Szilagyi, Delphine Deherder, Sarah Kavanagh, Mark Lebwohl

Page s646

Real-World Effectiveness of Guselkumab in Patients With Psoriasis: Data From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Luigi Naldi, Ahlem Azzabi, Steven Fakharzadeh, Wayne Gulliver, Fowzia Ibrahim, Yerkebulan Kambarov, Kimberly Parnell Lafferty, Wayne Langholff, Yayoi Tada, Miriam Zimmermann, Bruce Strober

Page s647

Real-World Assessment of Advanced Psoriasis Therapies in the US: Clinical Burden, Treatment Patterns, and Perceptions

Linda Stein Gold, Howard L. Sofen, Sakil Syeed, Kimberly Siu, Emily Edson Heredia, Beth Mitchell, Emily Goddard, Bruno Kranz, Liane Gillespie-Akar, April W. Armstrong

Page s648

Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting: 52-Week Data From the Phase 4 ARTISTYK Study

Steven R. Feldman, Todd Schlesinger, Leon H. Kircik, Jorge Garcia-Zuazaga, Orit Markowitz, James Del Rosso, Benjamin Lockshin, Raja K. Sivamani, Eugene Balagula, Andrew Napoli, Wei Zhu, Anna Begelfer, Yogita Kolekar, Yichen Zhong, April W. Armstrong

Page s649

Real-World Comparative Effectiveness of Deucravacitinib vs Apremilast at 6 Months for Plaque Psoriasis: Skin Clearance Outcomes From the RePhlect Study

April W. Armstrong, Mark Lebwohl, Swetha Srinivasan, Joe Zhuo, Yichen Zhong, Melinda Gooderham, Adam Sima, Robert R. McLean, Kim A. Papp, Joseph F. Merola, Alice B. Gottlieb, Stefan Varga, Bruce Strober

Page s651

Achievement of On‑Treatment Remission With Risankizumab in Patients With Moderate‑to‑Severe Psoriasis

April W. Armstrong, Tiago Torres, Joseph F. Merola, Brian Kirby, Mark G. Lebwohl, Tshepiso Madihlaba, Blair Kaplan, Richard Ta, Cuiyong Yue, Deepak M.W. Balak, Richard B. Warren

Page s653

Alopecia

Treatment-Induced Hair Shedding (Dread Shed) Associated with Androgenetic Alopecia Therapies

Aysham Chaudry, DO, Alexandra DeVries, Wilhelmina Lam, DO, MPH, Alec Lawson, Spencer Hawkins, MD, FAAD, Matt Leavitt, DO, Mark S. Nestor, MD, PhD

Page s654

A Systematic Literature Review of Alopecia Areata in Children and Adolescents: Psychosocial Impact

Brittany Craiglow, Lidia Rudnicka, Antonella Tosti, Kazutoshi Harada, Maryanne Senna, Manny Papadimitropoulos, Mehdi Hamza, Andrew Buchanan, Liliana Zaremba-Pechmann, Amy Paller

Page s656

Treatment of Alopecia with Low-Level Light Therapy

Aysham Chaudry, DO, Alec Lawson, Wilhelmina Lam, DO, MPH, Alexandra DeVries, Robert Vanaria, Mark S. Nestor, MD, PhD

Page s657

Baricitinib in the Treatment of Frontal Fibrosing Alopecia: Mid Trial Update

Alia Abbas, Tyler Downing, Chiemelum Amechi, Tiffany Mayo, Boni Elewski

Page s658

Most Baricitinib Responders Achieved Full Scalp Hair Regrowth: Findings from Adult and Paediatric BRAVE-AA Trials

Brett King, Justin Ko, Yutaka Shimomura, Melinda Gooderham, Rukhsar Chughtai, Samuel Ogwu, Samuel Ogwu, Najwa Somani, Lidia Rudnicka

Page s659

Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials

Thierry Passeron, Lisa Arkin, Manabu Ohyama, Ruth Ann Vleugels, Maryanne Senna, Yves Dutronc, Stephanie Chestnut Colvin, Tuhina Das, Angelina Sontag, Najwa Somani, Brittany Craiglow

Page s660

Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program

Brett King, Rodney Sinclair, Lidia Rudnicka, Sergio Vano-Galvan, Bianca Maria Piraccini, Manabu Ohyama, Wenyu ` Wu, Robert Wolk, Stephen Goodrich, Dalia Wajsbrot, Helen Tran, Alexandre Lejeune

Page s661

Baricitinib Provides Sustained, Long-Term Efficacy With Consistent Safety for Up to 5 Years of Treatment in Adults With Severe Alopecia Areata: Final Results From BRAVE-AA1 and BRAVE-AA2

Ruth Ann Vleugels , Bianca Maria Piraccini, Natasha Mesinkovska, Arash Mostaghimi, Yutaka Shimomura, Angelina Sontag, Fionn McSwiney, Hitendra Pandey, Karen Denning, Brett King

Page s662

Updated Integrated Safety Analysis of Ritlecitinib Up to ~5 Years in Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program

Maryanne Senna, Sameh Hanna, Rie Ueki, Xingqi Zhang, Crystal Aguh, Bianca Maria Piraccini, Edward Nagy, Alexandre Lejeune, Mojgan Sadrarhami, Simon Chen, Robert Wolk

Page s663

Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)

Arash Mostaghimi, Melinda Gooderham, Charles Lynde, Rodney Sinclair, Brett King, Maria Hordinsky, Lidia Rudnicka, Emma Guttman-Yassky, Sebastian Meerwein, Ahmed Soliman, Xianwei Bu, Chenyang Duan, Tianshuang Wu, Henrique Teixeira, Andreas Lazar, Thierry Passeron

Page s664

Impact of Severity and Disease Course on Baricitinib Treatment Response in Adolescent Patients with Severe AA from the BRAVE-AA-PEDS Trial.

Brittany Craiglow , Bianca Piraccini, Jennifer Soung, Manabu Ohyama, Lidia Rudnicka, David Saceda-Corralo, Angelina Sontag, Yves Dutronc, Hitendra Pandey, Kriti Singh, Lisa Arkin

Page s665

Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial

Brittany Craiglow, Lisa Arkin, David Saceda-Corralo, Young Lee, Manabu Ohyama, Yves Dutronc, Stephanie Colvin, Karen Denning, Sylvia Su, Tuhina Das, Ulrike Blume-Peytavi

Page s666

Baricitinib Provides Holistic Improvement in Scalp, Eyebrow and Eyelash Regrowth in Adolescents With Severe Alopecia Areata

Bianca Maria Piraccini, Manabu Ohyama, Lisa Arkin, Arash Mostaghimi, Angelina Sontag, Kriti Singh, Tuhina Das, Jennifer Soung

Page s667

Baricitinib Effectiveness and Patient Impressions in Routine Clinical Practice: 12-month Results from a Prospective Observational Real-world Study

Justin Ko, Tiffany Mayo, Crystal Aguh, Susan Ball, Angelina Sontag, Firas Dabbous, Mary Kate Ladd, Klaudia Kornalska, Najwa Somani, Jerry Shapiro

Page s668

Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials

Lidia Rudnicka, Juliette Mazereeuw-Hautier, Ilka Arun Netravali, Kazutoshi Harada, Cheng Zhou, Katya L. Harfmann, Dalia Wajsbrot, Edward Nagy, Alanna Chaudhry, Robert Wolk, Helen Tran

Page s669

Effectiveness of Baricitinib for Nasal, Genital, and Beard Hair Regrowth in Patients with Severe Alopecia Areata: 12-Month Outcomes from a Prospective Observational Study

Justin Ko, Karan Lal, Michelle Tarbox, Susan Ball, Angelina Sontag, Firas Dabbous, Mary Kate Ladd, Klaudia Kornalska, Najwa Somani, Jerry Shapiro

Page s670

Updated Integrated Efficacy Analysis of Ritlecitinib Up to 3 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials

Lidia Rudnicka, Juliette Mazereeuw-Hautier, Ilka Arun Netravali, Kazutoshi Harada, Cheng Zhou, Katya L. Harfmann, Dalia Wajsbrot, Rahmat Adejumo, Alanna Chaudhry, Robert Wolk, Helen Tran

Page s671

Acne & Rosacea

Efficacy of Oral DFD-29, a Low-Dose Minocycline Formulation, in Patients With Rosacea: A Pooled Analysis of Two Phase 3 Trials

Neal Bhatia, MD, James Del Rosso, DO, Linda Stein Gold, MD, Edward Lain, MD, Zoe Diana Draelos, MD, Dr. Srinivas Sidgiddi

Page s696

Current Topical Treatment Approaches for Managing Acne Associated with Janus Kinase Inhibitors

Christopher G. Bunick, Naiem T. Issa, Julie C. Harper, Hilary Baldwin, Joshua A. Zeichner, Leon H. Kircik

Page s697

Efficacy and Safety of Fixed-Dose Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel in Asian Participants With Moderate to Severe Acne

George Han, Andrew F. Alexis, Neal Bhatia, Valerie D. Callender, Hilary Baldwin, Eric Guenin, Linda Stein Gold

Page s698

Long-Term Efficacy and Tolerability of Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Acne: Pooled Results From Two 6-Month Studies

Zoe D. Draelos, Hilary Baldwin, Julie C. Harper, Mahmound Ghannoum, Linda Stein Gold, Emil A. Tanghetti, Eric Guenin, Leon Kircik

Page s699

Use of Oral Sarecycline as Monotherapy and in Combination With Topical Treatments in Patients With Acne: A Post-Hoc Analysis of Results From the Patient Reported Outcomes for Sarecycline Effectiveness and Safety (PROSES), a Single-Arm Prospective Cohort Study

Hilary Baldwin, MD, Elizabeth Swanson, MD, Adam Friedman, MD, Joshua Zeichner, MD, Danielle Dubin, MD, Shanna Miranti MPAS, PA-C, Raidah Salem, PharmD, MBA, Paul Tomondy, PharmD, Emmy Graber, MD, MBA

Page s700

Melanoma

Non-Melanoma Skin Cancers and Benign Cutaneous Tumors

An Evaluation of the Safety and Efficacy of Aminolevulinic Acid Hydrochloride Topical Gel, 10% with Red Light in the Treatment of Facial Cutaneous Squamous Cell Carcinoma in situ

Aysham Chaudry, DO, Robert J. Vanaria, BS, Wilhelmina Lam, DO, Alexandra DeVries, BS, Alec Lawson, Mark S. Nestor MD, PhD

Page s682

Red Light Photodynamic Therapy with 10% Aminolevulinic Acid Gel Showed Robust Efficacy for the Treatment of Superficial BCC in a Randomized, Vehicle-Controlled, Double-Blind, Multicenter Phase III Study

Todd Schlesinger, MD, FAAD, M. Shane Chapman, MD, MBA, John H. Tu, MD, MS, Joel L. Cohen, MD, John Strasswimmer, MD, PhD, FAAD, FACMS, Nathalie C. Zeitouni, MD, Abel Torres, MD, JD, MBA, Sasha Jazayeri, MD, Mitchel P. Goldman, MD, Sherrif F. Ibrahim, MD, PhD, Edward L. Lain, MD, MBA, Megan P. Couvillion, MD, MS, Suzanne Bruce, MD, Vivian T. Laquer, MD, C. William Hanke, MD, MPH, FACP, David M. Ozog, MD, Jane Schneider, MD, Orit Markowitz, MD, FAAD, Brian Berman, MD, PhD, Mark S. Nestor, MD, PhD, Michael H. Gold, MD, Girish S. Munavalli, MD, MHS, FAAD, FACMS, Douglass W. Forsha, MD, Daniel M. Siegel, MD, David Mrohs, PhD, Beate Schmitz, PhD, Ruth Schäning, MSc, Nicole Pospiech, PhD, Jon Lyons, PhD, MBA, Montserrat Foguet, PhD, Matthias Lübbert, PhD, Hermann Lübbert, PhD, David M. Pariser, MD

Page s683

Limitations of Modern Sunscreens: Implications for UVA Protection and Skin Cancer Prevention

Alexandra DeVries, Aysham Chaudry, DO, Alec Lawson, Wilhelmina Lam, DO, MPH, Mark S. Nestor, MD, PhD

Page s685

Aminolevulinic Acid 20% Topical Solution Activated by Blue Light in the Treatment of Facial Cutaneous Squamous Cell Carcinoma in situ

Alec Lawson, Wilhelmina Lam, DO, MPH, Alexandra DeVries, Aysham Chaudry, Robert Vanaria, Mark S. Nestor, MD, PhD

Page s686

An Evaluation of the Safety and Efficacy of Aminolevulinic Acid Hydrochloride Topical Gel, 10% with Red Light in the Treatment of Facial Cutaneous Squamous Cell Carcinoma in situ

Aysham Chaudry, DO, Robert Vanaria, Wilhelmina Lam, DO, MPH, Alexandra DeVries, Alec Lawson, Mark S. Nestor, MD, PhD

Page s687

Clinical and Patient-Reported Outcomes (PROs) in C-POST: A Phase 3 Trial of Adjuvant Cemiplimab Versus Placebo for High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

Danny Rischin, Chieh-I Chen, Sandro Porceddu, Fiona Day, Daniel P Brungs, Hayden Christie, James E Jackson, Brian N Stein, Yungpo Bernard Su, Rahul Ladwa, Gerard Adams, Samantha E Bowyer, Zulfiquer Otty, Naoya Yamazaki, Paolo Bossi, Amarnath Challapalli, Axel Hauschild, Vishal A Patel, Joanna Walker, Maite De Liz Vassen Schurman, Paola Queirolo, Javier Cañueto, Flavio Augusto Ferreira da Silva, Alexander Stratigos, Alexander Guminski, Shikha Bansal, Camryn Joseph, Frank Seebach, Suk-Young Yoo, James Harnett, Lei Chi, Priscila Goncalves, Matthew G Fury, Annette M Lim

Page s688

Trial in Progress: A Phase 3 Randomized Study of Low-Dose Intralesional Cemiplimab Versus Primary Surgery for Patients With Early-Stage Cutaneous Squamous Cell Carcinoma (CLEAR CSCC)

Michael Midgen, Sherrif Ibrahim, John Strasswimmer, Nathalie Zeitouni, Suk-Young Yoo, Frank Seebach, Israel Lowy, Mihaela Cristea, Matthew Fury

Page s689

Psoriatic Arthritis

Maintenance of Response to Risankizumab in Patients With Psoriatic Arthritis: A 5-year Analysis of the KEEPsAKE 1 and 2 Trials

Andrew Östör, Ahmad S. Amin, William Tillett, Sarah Lonowski, Boussad Ait-Challal, Hayato Yamazaki, Cuiyong Yue, Hayley Barnard, Joseph F. Merola

Page s691

Long-Term Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 244-Week Results From the KEEPsAKE 2 Trial

Andrew Östör, Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion, Tshepiso Madihlaba, Thomas Iyile, Lingfeng Luo, Christopher D. Saffore, Doug Ashley, Arathi R. Setty, Hayato Yamazaki, Alan Kivitz

Page s692

High Body Mass Index (BMI) Psoriasis is Associated With a Higher Prevalence of Cardiometabolic Disease, Psoriatic Arthritis, and Systemic Inflammation

Joseph Merola, Mark Lebwohl, Christopher E.M. Griffiths, Yukari Okubo, Rishabh Bahl, Bomina Park, Najwa Somani

Page s693

Obesity Is Associated With Residual Disease Activity and Lower Quality of Life in Patients Who Achieve Clinical Response to Psoriatic Arthritis Treatment: Post Hoc Analysis From the SPIRIT Studies

Joseph F. Merola, William Tillett, Uta Kiltz, Elizabeth L. Perkins, Allyson Perry, Marcus Ngantcha, Blessing Ibe, Russel Burge, Andris Kronbergs, Norman Madsen

Page s694

Drug Survival of Risankizumab vs Other Biologics After 25 Months of Treatment Among Patients With Psoriatic Arthritis: An Interim Analysis of the VALUE Study

Andrew Östör, Kim A Papp, Hongwei Wang, Vassilis Stakias, Ralph Lippe, Tshepiso Madihlaba, Diamant Thaçi

Page s695

Mycoses

Successful In Vitro and In Vivo Treatment of Tinea Pedis with a Nitric Oxide-releasing Gel

Harmanpreet Kaur, Najmeh Dorafshanian, James Martins, Simon Teskey, Chris Miller

Page s701

A Novel Topical Nitric Oxide Releasing Gel Demonstrates Effective Nail Penetration and Potent Antifungal Activity in Onychomycosis

Aditya Gupta, Elizabeth Cooper, Harmanpreet Kaur, James Martins, Simon Teskey, Chris Miller

Page s702

Clinical Findings in Cryptococcoid Neutrophilic Dermatosis: A Review of theLiterature and Single-Center Retrospective Study

Michael Tang, Grace Herron, Anne Ning, Yolanda Helfrich, Lori Lowe, Severine Cao

Page s703

Review of the Clinical Efficacy and Safety of Efinaconazole 10% Topical Solution for Onychomycosis Across Subgroups

Ted Rosen, Aditya K. Gupta, Linda Stein Gold, Leon H. Kircik, Tracey C. Vlahovic, Eric Guenin, Shari R. Lipner, Fran E. Cook-Bolden, Boni Elewski

Page s704

Hidradenitis Suppurativa

Real-World Dosing Patterns of Biologics for the Treatment of Hidradenitis Suppurativa

Pelin Ozluk, Benjamin Chastek, Laura Becker, Chike Okoro, Jeannette Novatski

Page s705

Bimekizumab impact on flare in hidradenitis suppurativa over 2 years: Data from BE HEARD EXT

Haley B. Naik, Steven Daveluy, Errol Prens, Ziad Reguiai, Pablo Fernandez-Peñas, Sayaka Yamaguchi, Bartosz Lukowski, Christina Crater, Leah Davis, Antonio Martorell

Page s706

Bimekizumab clinical efficacy responses translate into improvements in patient outcomes to Week 48 in patients with moderate to severe hidradenitis suppurativa: Results from BE HEARD I&II

Alexa B. Kimball, Amit Garg, Hadar Lev-Tov, Kelsey R. van Straalen,, Evangelos J. Giamarellos-Bourboulis, Koremasa Hayama, Bartosz Lukowski, Robert Rolleri, Jérémy Lambert, Tom Vaux, Linnea Thorlacius

Page s707

Hyperpigmentation

Clinical Evaluation of Thiamidol-containing Formulations for the Visual Management of Facial Hyperpigmentation

Seemal Desai, MD, Edward (Ted) Lain, MD, MBA , Nada Elbuluk, MD , Cheri Frey, MD

Page s708

Thiamidol: A Breakthrough Innovation in the Treatment of Hyperpigmentation

Cheri Frey, MD, Pearl E. Grimes, MD, Valerie D. Callender, MD , Andrew Alexis, MD, MPH, Hilary Baldwin, MD , Nada Elbuluk, MD , Patricia Farris, MD , Susan Taylor, MD, Seemal Desai, MD

Page s710

Dermatopharmacology

Integrated Safety Analysis of Ruxolitinib Cream: Data From 20 Clinical Studies in Inflammatory Dermatologic Conditions

Karen Miller; Christopher G. Bunick, Khaled Ezzedine, Lawrence F. Eichenfield, Robert Bissonnette, Thierry Passeron, Daniel Sturm, Haobo Ren, Yun Su, David Rosmarin

Page s711

KT-621, an Oral, Once Daily, Targeted STAT6 Degrader: First-in-Human Phase 1a Safety, Pharmacokinetics, Pharmacodynamics and Th2 Biomarker Effects

Arsalan Shabbir, Sagar Agarwal, Alice McDonald, Kelvin Shi, Annie Conery, Mahta Mortezavi, Nello Mainolfi, Jared Gollob,, Chad Nivens

Page s712

Vitiligo

Real-World Patient Experience With Ruxolitinib Cream in Vitiligo

Swapna Ambati, Dan Sturm, Chris O’Brien, Beth Schneider

Page s713

Description of the 3 Tranquillo Phase 3 clinical program study designs to assess ritlecitinib treatment in adults and adolescents with nonsegmental vitiligo

Tatjana Lukic, Pranab Ghosh, Lynne Napatalung, Cunshan Wang, Iltefat Hamzavi, Rodney Sinclair, Leihong Xiang, Kenneth Steil, David Rosmarin, Davinder Parsad, Khaled Ezzedine, Roni Adiri

Page s714

Pruritus & Prurigo Nodularis

Dupilumab-Treated Patients With Prurigo Nodularis Experience Improvements in Itch and Skin Pain: 6-Month Results From the RELIEVE-PN Study

Shawn G Kwatra, Ryan B Thomas, Donia Bahloul, Joseph Zahn, Samreen Arshad, Bruno Martins, Min Yang, Jiaxuan Liu, Allister Ho, Sarina B Elmariah

Page s715

Dupilumab-Treated Patients With Prurigo Nodularis Report Disease Control and Treatment Satisfaction: 6-Month Results From the RELIEVE-PN Study

Sarina B Elmariah, Ryan B Thomas, Donia Bahloul, Joseph Zahn, Samreen Arshad, Min Yang, Bruno Martins, Allister Ho, Jiaxuan Liu, Shawn G Kwatra

Page s716

Hyperhidrosis

Chronic Hand Eczema

Demographics, Clinical, and Treatment Characteristics of Patients With Moderate to Severe Chronic Hand Eczema in the United States – A Retrospective Claims Analysis

April Armstrong, Rebecca Burne, Aseel Bin Sawad, Anais Lemyre, Marjolaine Gauthier-Loiselle, Annie Guerin, Tanzania Vinson, Brent Milovac, Sanjeev Balu

Page s672

Demographics and Clinical Characteristics of Chronic Hand Eczema patients – Results from the CHECK study in the United States

Eric Simpson, Sanjeev Balu, Aseel Bin Sawad, Eydna Didriksen Apol, Shannon Schneider, Douglas Maslin, Lysel Brignoli, Alissar Moussalem, Raj Chovatiya

Page s674

Healthcare Resource Utilization and Financial Burden Among Patients With Chronic Hand Eczema – Results From the CHECK Study in the United States

Raj Chovatiya, Sanjeev Balu, Aseel Bin Sawad, Eydna Didriksen Apol, Shannon Schneider, Douglas Maslin, Bleuenn Rault, Alexanne Morillo, Eric Simpson

Page s675

Prevalence of Self-Reported Physician Diagnosis of Chronic Hand Eczema in Adults: A Cross-Sectional Study of More Than 10,000 Participants in the General Population – Results From the CHECK Study in the United States

Raj Chovatiya, Sanjeev Balu, Aseel Bin Sawad, Eydna Didriksen Apol, Shannon Schneider, Douglas Maslin, Lysel Brignoli, Perrine Le Calvé, Eric Simpson

Page s676

Self-Reported Disease Severity, Symptoms, and Treatment of Chronic Hand Eczema – Results From the CHECK Study in the United States

Raj Chovatiya, Sanjeev Balu, Aseel Bin Sawad, Eydna Didriksen Apol, Shannon Schneider, Douglas Maslin, Bleuenn Rault, Alexanne Morillo, Eric Simpson

Page s677

The Impact of Chronic Hand Eczema on Occupation, Work Productivity, and Activity Impairment – Results From the CHECK Study in the United States

Eric Simpson, Sanjeev Balu, Aseel Bin Sawad, Eydna Didriksen Apol, Shannon Schneider, Douglas Maslin, Lysel Brignoli, Alissar Moussalem, Raj Chovatiya

Page s678

Hand Eczema Workers’ Compensation Claims: Real-World Data Analysis in the United States

Richard Brook, Aseel Bin Sawad, Ian Beren, Eric Rosenberg, Nathan Kleinman, Brent Milovac, Sanjeev Balu, Joel Gelfand

Page s679

Cost-Per-Responder Analysis of Delgocitinib Topical Cream Versus Dupilumab Subcutaneous Injection for Moderate to Severe Atopic Hand Eczema in the United States

Sanjeev Balu, Amanda Falah Rasmussen, Aseel Bin Sawad, Eydna Didriksen Apol, Pravin Kamble, Douglas Maslin, Anne Sofie Loftager

Page s680

Budget Impact Analysis of Delgocitinib Cream for Moderate to Severe Chronic Hand Eczema in the United States

Jianni Singh-Landa, Aseel Bin Sawad, Yasmin Bappoo, Ben Llewellyn, Megan Barnes, Douglas Maslin, Sanjeev Balu

Page s681

Miscellaneous

Wound Healing: Mechanisms, Advanced Management, and the Evolving Role of the Dermatologist

Wilhelmina Lam, DO, MPH, Alec Lawson, Aysham Chaudry, DO, Alexandra DeVries, Mark S. Nestor, MD, PhD

Page s719

Prevention and Management of Radiation Dermatitis: Variation Based on Anatomic Target

Alexandra DeVries, Wilhelmina Lam, DO, MPH, Alec Lawson, Aysham Chaudry, DO, Robert Vanaria, Mark S. Nestor, MD, PhD

Page s720

From Familiar to Foundational: CME-Informed Learning Needs in Dermatologic Management of CSU, AD, and PN

April Armstrong, MD, MPH, Brad Glick, DO, MPH, Shawn Kwatra, MD, David Lang, MD, Mark Lebwohl, MD, Sandra Lee, MD, Dawn Merritt, DO, Tejesh Patel, MD, Mona Shahriari, MD, Marc Serota, MD, Michelle Tarbox, MD, Jeremy Levine, BS, Kasey Brandt, PharmD, Sumera Ackbarali, PhD, CHCP, Sonia Schursky, MD

Page s721

Avapritinib Durably Improves Cutaneous Involvement of Indolent Systemic Mastocytosis in Patients Treated in the PIONEER Study

Golder Francis; Frank Siebenhaar, Sigurd Broesby-Olsen, Tracy I. George, Hanneke Oude Elberink , Stephen Oh, Hui-Min Lin, Ilda Bidollari, Janet Hong, Lauren Madigan, Karen Hartmann

Page s722